Early Detection of Pancreatic Cancer: Unlocking the Power of ZFP30 and ZNF781 Methylation Markers
Gaps and Limitations in Pancreatic Cancer Diagnosis
Pancreatic cancer is notoriously difficult to detect early, with most cases diagnosed at an advanced stage. Common tumor markers like CA19-9 and CEA often lack the sensitivity and specificity needed to guide timely treatment decisions.
Research Advances
In collaboration with Taipei Medical University, EG BioMed analyzed cfDNA methylation of the ZFP30 and ZNF781 genes. Preliminary results revealed abnormal hypermethylation of both genes in pancreatic cancer patients, detectable through blood samples. This study was presented at the 2025 annual meetings of the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) by Dr. Ruo-Kai Lin, a professor at Taipei Medical University and Chief of R&D at EG BioMed. Expanded validation is currently underway to evaluate its potential as a non-invasive tool for early detection.
The EG-Pancreatic blood test-E1 demonstrated outstanding diagnostic performance in detecting pancreatic cancer, particularly among early-stage patients. Validation across both Asian and Western cohorts confirmed that methylation detection of ZFP30 and ZNF781 offers a safe, accurate, and feasible non-invasive approach for early pancreatic cancer screening. This method improves clinical diagnostic efficiency and supports early intervention and personalized care planning for high-risk individuals, helping patients detect disease earlier and improve prognosis.
Professor Ruo-Kai Lin of Taipei Medical University, who currently serves as Chief of Research and Product Development at EG BioMed, presented this research at AACR 2025.
Want to stay updated on EG BioMed’s latest technologies and research progress?
Follow us on LinkedIn、Facebook, and Instagram for real-time updates and insights!